Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Novacyt launches IVDR-certified Yourgene Insight DPYD test in Europe
Novacyt has introduced the IVDR-certified Yourgene Insight DPYD test for the European market and can now commercially distribute it in regulated markets. The test detects 19 clinically relevant variants in the DPYD gene, including all current tier‑1 and tier‑2 variants, and according to the company is the first CE-marked DPYD test under the IVDR with this variant coverage. Novacyt developed the product with clinicians and previously offered the test in May 2026 as research-use-only. » Más en de.investing.com
Novacyt achieves 18% revenue growth in first half of 2026
Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » Más en de.investing.com
Novacyt publishes annual report and financial statements for 2025
Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » Más en de.investing.com
Novacyt schedules general meeting for 30 June and announces investor presentation
Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » Más en de.investing.com
Novacyt: CSO Joanne Mason resigns with immediate effect
Novacyt said Dr. Joanne Mason is stepping down from her role as chief scientific officer and board member with immediate effect to pursue new professional opportunities. Mason served in the role for six years and helped shape the scientific direction and R&D foundations of the molecular diagnostics company. The company gave no information on a successor or further details. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 13,27 M | 132,65 % |
| Beneficio bruto | 6,14 M | 22,44 % |
| Beneficio neto | -6,65 M | 78,95 % |
| EBITDA | -4,46 M | 73,39 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 37,7 M € |
Número de acciones | 72,47 M |
Máximo/mínimo de 52 semanas | 0,52 € - 0,44 € |
| Dividendos | No |
Beta | 1,11 |
Ratio P/E | -0,76 |
Ratio PEG | -0,04 |
Ratio P/B | 1,42 |
Ratio P/S | 0,81 |
Perfil de la empresa
Novacyt S.A., junto con sus filiales, se dedica al desarrollo, la fabricación, el diseño por contrato y la comercialización de productos de diagnóstico para el cáncer y las enfermedades infecciosas en el Reino Unido, el resto de Europa, Estados Unidos, Asia-Pacífico, Oriente Medio y África. Opera a través de Primer Design, Lab21 Products e IT-IS International. El segmento Primer Design diseña, fabrica y comercializa dispositivos y reactivos de pruebas moleculares de PCR en tiempo real (qPCR) en el ámbito de las enfermedades infecciosas. El segmento Lab21 Products desarrolla, fabrica y distribuye una gama de productos de diagnóstico in vitro (IVD) basados en proteínas para enfermedades infecciosas. El segmento IT-IS International desarrolla y fabrica dispositivos de PCR para la industria de las ciencias de la vida y de las pruebas alimentarias. Atiende a hospitales y empresas. La compañía se constituyó en 2006 y tiene su sede en Vélizy-Villacoublay, Francia.
| Nombre | Novacyt |
| CEO | Lyn Dafydd Rees |
| Sede | Le Vésinet,
if Francia |
| Sitio web | |
| Salida a bolsa | 12/10/2012 |
| Empleados | 234 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Euronext | ALNOV.PA |
London Stock Exchange | NCYT.L |
Pnk | NVYTF |
Frankfurt | NYZ.F |
Düsseldorf | NYZ.DU |
London | NCYT.L |
Paris | ALNOV.PA |
München | NYZ.MU |